Litcius/Paper detail

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, Weixiao Han, Zhen Chen, Rong Tang, Weidong Yin, Xin Chen, Yuansheng Hu, Xiaoyong Liu, Congbing Jiang, Jingxin Li, Minnan Yang, Yan Song, Xiangxi Wang, Qiang Gao, Fengcai Zhu

2020The Lancet Infectious Diseases1,508 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTolerabilityPlaceboVaccinationCohortClinical trialInternal medicineRandomized controlled trialAdverse effectImmunologyPathologyAlternative medicineSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responsesvaccines and immunoinformatics approaches
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial | Litcius